Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Double chin

- PMLiVE

US and Indian regulators forge closer ties

FDA signs new agreement with India's Ministry of Health and Family Welfare

Bayer symbol

Bayer drug cuts infusion burden in haemophilia A

Able to provide longer-term protection against bleeding episodes in late-stage trial

- PMLiVE

Actavis ‘negotiating $25bn acquisition’ of Forest

Generic company reportedly in late-stage takeover talks

- PMLiVE

FDA backs BioMarin drug for rare enzyme disorder

Vimizim is first drug approved in US under rare paediatric disease priority review

- PMLiVE

FDA knocks back J&J and Bayer’s Xarelto in ACS

Follows unanimous negative committee vote

- PMLiVE

FDA knocks back Durect’s painkiller

Regulator wants more safety information for Posidur

- PMLiVE

FDA clears J&J’s Imbruvica for leukaemia

Adds to cancer drug's lymphoma indication

- PMLiVE

FDA to review safety of AZ’s saxagliptin

Diabetes drug linked to heart failure

- PMLiVE

FDA deems GSK anaemia drug a ‘breakthrough’

US regulator will accelerate review of Promacta

- PMLiVE

Interview: Julia Kendrick

Allergan's in-house PR counsel on winning Communiqué 2013's Young Achiever

- PMLiVE

FDA approves sleep disorder drug for blind people

Vanda Pharmaceuticals wins backing for Hetlioz to improve a person’s body clock

China flag thumb

Actavis divests another Chinese interest

Reduces presence in “risky” market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links